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Background: Lockdown measures have been enforced globally in response to the
COVID-19 pandemic. Given the comorbidity burden in women with polycystic ovary
syndrome (PCOS), these lockdown measures may have a particularly negative impact
on sleep health, quality of life (QoL), and depression/stress levels in this population. The
aim of this study was to explore whether such potential problems were present in women
with PCOS during the COVID-19 lockdown in the UK.
Methods: UK women with PCOS were recruited through social media into a
cross-sectional study during the COVID-19 lockdown. The study survey was delivered
online, and included demographic and COVID-19 relevant questions, as well as validated
questionnaires/scales, namely the Insomnia Severity Index (ISI), Depression Anxiety and
Stress Scale (DASS-21), and PCOSQOL questionnaire.
Results: Three hundred and thirty-three women with PCOS [median age: 30.0 (9.0)
years] were recruited. Participants were dichotomized based on responses regarding
the impact of COVID-19 restrictions on their sleep [negative (N = 242) vs. no/positive
(N = 91) impact]. No differences were noted between groups regarding age, time since
PCOS diagnosis, body mass index, or number of comorbidities. Based on the ISI,
44.2% of participants reporting a negative impact on sleep exhibited at least moderately
severe clinical insomnia. Compared to those who reported no/positive effect on sleep,
the participants reporting a negative impact on sleep also reported poorer QoL, based
on the total PCOSQOL score, with a greater impact of PCOS and poorer mood in
the corresponding PCOSQOL domains. Based on the DASS-21, the latter also had
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statistically higher depression and stress levels compared to the former. Finally, for this
cohort significant inverse correlations were noted between the ISI and PCOSQOL scores
(total and domain scores), whilst the DASS-21 and ISI scores were positively correlated
(all p-values <0.001).
Conclusion: The majority of recruited UK women with PCOS reported that the
COVID-19 lockdown had a negative impact on their sleep, which was also associated
with impaired QoL and higher depression/stress levels. Whilst further research is required,
women with PCOS should be considered a vulnerable population that may experience an
adverse impact on sleep, QoL and mental health well-being due to lockdown measures
during the COVID-19 pandemic.
Keywords: polycystic ovary syndrome, COVID-19, lockdown, sleep, anxiety, depression, stress, quality of life
INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2),
usually manifests as a respiratory tract infection with mild
symptomatology (asymptomatic in many cases) (1–3). However,
COVID-19 can also lead to severe manifestations in a proportion
of high-risk individuals with respiratory and/or extra-pulmonary
symptoms/complications requiring hospitalization (1–3). As
the latter may require intensive care unit (ICU) support and
may even be fatal, the COVID-19 pandemic has resulted
in enforcement of varying degrees of nationwide lockdown,
quarantine and self-isolation measures in many countries
worldwide (4, 5). These measures aim to reduce SARS-CoV-2
transmission in the general population, and thus the risk of
severe COVID-19 in vulnerable groups (e.g., older individuals
and patients with certain respiratory and cardio-metabolic
diseases) (6–12). Indeed, compelling evidence strongly indicates
that certain chronic cardio-metabolic diseases, including diabetes
and obesity, constitute key risk factors predisposing to severe
COVID-19 (6–12). Notably, although severe COVID-19 is more
common in men (13, 14), the aforementioned cardio-metabolic
comorbidities, which significantly increase the risk of adverse
COVID-19 related clinical outcomes, are also markedly prevalent
in women with polycystic ovary syndrome (PCOS) (15–17).
PCOS is the most common endocrine disorder in
reproductive-aged women, affecting up to 15–20% of this
female population depending on the studied population and
the applied diagnostic definition (18, 19). After excluding other
endocrinopathies with similar symptomatology (19, 20), PCOS
is typically diagnosed based on the presence of at least two
out of three diagnostic criteria, namely ovulatory dysfunction,
hyperandrogenism (clinical and/or biochemical) and polycystic
ovaries (PCO) as identified by ultrasound (21). In addition,
women with PCOS are also at a high risk of cardio-metabolic
complications, particularly obesity, insulin resistance, type
2 diabetes (T2DM), hypertension, non-alcoholic fatty liver
disease (NAFLD), and obstructive sleep apnoea (OSA) (22–27).
Furthermore, women with PCOS often exhibit psychological
comorbidity, with higher prevalence of coexisting anxiety
and/or depression (28–31), which also tends to impair their
overall quality of life (QoL) compared to women without PCOS
(32, 33). Given this increased comorbidity burden, women
with PCOS may experience a particularly negative impact from
the lockdown/quarantine and self-isolation measures imposed
against the transmission of SARS-CoV-2 and may also be at
increased risk of severe COVID-19 (16).
Overall, global measures to control the COVID-19 pandemic
are expected to inevitably have a negative psychological effect
upon the general population (34) due to various factors,
including the enforced quarantine measures (35) and their
socio-economic impact (36), as well as the concern about
COVID-19 (34). This has been previously reported in relation
to SARS, which was shown to promote increased stress,
anxiety and depression in the general population (37). Such
findings are increasingly reported during the current COVID-19
pandemic, with an observed increase in self-reported symptoms
of anxiety, depression, and stress (38). Moreover, these negative
psychological effects are likely linked to disrupted sleep quality
(39). In previous longitudinal studies, new onset mental health
issues have been linked to increased sleep disruption (40–42),
whilst disturbed sleep is also considered to be a contributing
factor to the development of new mental health disorders
(43). Of note, irrespective of the COVID-19 pandemic, sleep
disturbances aremore prevalent in womenwith PCOS than in the
general population (44, 45), potentially due to coexisting OSA,
particularly in womenwith poorermetabolic profiles (26), and/or
depression which is also a major predictor of poor sleep quality
(46). Furthermore, reduced self-esteem and body satisfaction,
which are both frequently associated with PCOS, have also been
demonstrated to contribute toward disrupted sleep (44).
In this context, it is likely that a 2-fold effect of increased
psychological distress due to the COVID-19 pandemic alongside
the established disease-related burden of PCOS may further
contribute to impaired sleep quality and QoL, linked also
to increased anxiety, depression, and stress levels (47). To
date, there have been no published studies exploring these
issues in women with PCOS during the COVID-19 pandemic.
Therefore, the aim of the current study was to determine whether
the COVID-19 pandemic has had a negative effect upon the
sleep quality of women with PCOS in the United Kingdom
(UK), and whether any such impairment was associated with
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reduced QoL and increased stress, anxiety, or depression in this
female population.
METHODS
For the purposes of this study, we conducted a cross-sectional
study based on a web-based survey between 2nd June and
17th August 2020. Ethical approval was granted by the
ethics committee of Coventry University (application number:
P106195) in May 2020. Recruitment was conducted through
social media and with the support of Verity (the UK PCOS
charity) and PCOS support groups on Facebook. Participant
eligibility criteria included female sex with a previous medical
diagnosis of PCOS, age from 18 to 45 years, and UK residency.
A range of structured and validated questionnaires were
used to collect the study data; questionnaires were completed
online using the survey software, Qualtrics© XM (Qualtrics XM,
Provo, Utah, USA). Where participants expressed an interest
in participation, a study URL link to the survey was emailed
to them directly. Alternatively, participants could access the
questionnaires directly via the same study URL posted on
social media channels. The study URL link contained an initial
participant information sheet, as well as provision of informed
consent. Where participants failed to complete the provided
online survey, this was translated as withdrawal from the study
and all data for these participants were excluded from the
final analyses.
To capture relevant participant characteristics, a
demographics questionnaire was created for this survey.
This included self-reported information about time since PCOS
diagnosis and diagnosed PCOS phenotype, height, weight, age,
questions relating to sleep affected by COVID-19 restrictions
(i.e., “to what extent do you believe that quarantine measures
due to COVID-19 have affected your sleep pattern?”), presence
of comorbidities and typical sociodemographic questions. In
the context of this study, the PCOSQOL was utilized as a
validated measure of QoL (48). The PCOSQOL is a disease-
specific questionnaire which was developed and validated to
measure QoL in UK women with PCOS, and is also the first
PCOS-specific measurement tool to encompass all phenotypic
subgroups according to the most recent diagnostic criteria (48).
Briefly, this questionnaire incorporates 35 Likert-based questions
allowing participants to report the impact of various PCOS-
related symptoms upon their day-to-day life, with subscales
which allow reporting of the impact of PCOS, infertility,
hirsutism, and mood upon QoL (49–51). Total scores are
summated with lower scores indicative of poorer QoL.
Information about the mental health well-being of each
participant was also captured using the Depression, Anxiety
and Stress Scale (DASS-21) (52). The DASS-21 includes 21
questions, seven relating to each domain for depression, anxiety
and stress, and requires respondents to rate their level of
agreement (0–3) to a series of statements. Each domain score is
calculated by summing the responses and multiplying by two,
whilst normative and cut-points for depression, anxiety, and
stress are provided. Finally, the Insomnia Severity Index (ISI)
was applied to measure participants’ self-perceived insomnia
(53), as a validated and reliable tool for the assessment of
insomnia severity (54, 55). The ISI targets the subjective
symptoms and consequences of insomnia, as well as the degree
of concerns or distress caused by those difficulties. The ISI
is composed of seven items that, respectively, evaluate the
severity of sleep-onset (initial), sleep maintenance (middle),
early morning awakening problems (terminal), satisfaction
with current sleep pattern, interference with daily functioning,
noticeability of impairment attributed to the sleep problem,
and level of distress caused by the sleep problem. Each
of these items is rated on a five-point Likert scale and
the time interval is “in the last 2 weeks.” Total ISI scores
range from 0 to 28, with higher scores indicating greater
insomnia severity.
Statistical Analysis
Statistical analysis was completed in IBM SPSS Statistics for
Windows (Version 26.0, IBM Corp; Armonk, NY) and in R
statistical software [(56), using the car: and MASS: packages]
(57, 58), and statistical significance was set at p < 0.05.
Descriptive characteristic reports were generated and Shapiro-
Wilk tests of normality were completed. Accordingly, a non-
parametric approach was adopted for subsequent analysis,
as appropriate. Responses to the question “to what extent
do you believe that quarantine measures due to COVID-
19 have affected your sleep pattern?” were split into a
dichotomous response—namely, into negative effects or no
effect/positive effects—which was used as a categorical variable.
Independent samples Mann-Whitney U-tests were completed to
evaluate the between group differences. Spearman’s correlations
between the ISI and other questionnaires (i.e., PCOSQOL
total and domain scores, and the DASS-21) were also
completed for the entire study cohort and also within
each group.
Given the Likert scale nature of the data in this study, where
Likert scales are a special case of ordinal data, we utilized an
ordinal logistic regression (OLR) approach. The OLR approach
is comparable to a conventional multiple regression approach,
where there may be one dependent variable and one or more
independent variables. It does however differ from ordinary least
squares multiple regression, by treating the dependent variable
as an ordered categorical variable, based upon the principle
of cumulative-odds (59). The coefficient of determination, R2,
summarizes the proportion of variance in the dependent variable
associated with the independent variables, with larger R2 values
indicating that more of the variation is explained by the model,
to a maximum of 1. However, in non-parametric regression,
it is not possible to compute a traditional R2, and a pseudo
R2 is computed instead. In this study, we opted to report
Nagelkerke’s R2 (R²N), which is an adjusted version of the
Cox & Snell R2 that adjusts the scale of the statistic to cover
the full range from 0 to 1 (60, 61). To test the statistical
significance of each model coefficient (β), we used the Wald
test to compute a Wald statistic with a chi-square distribution.
All participant background characteristics were adjusted for in
the OLR.
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RESULTS
In total, 333 participants met the eligibility criteria and consented
to participate in the present study, completing the online survey.
Pertinent demographics/characteristics for the recruited study
cohort are presented in Table 1. The vast majority of the study
participants (92.5%) were of White ethnic background. Of the
recruited cohort, 40% were married and a further 40% were
single, with the remaining 20% being in other non-married
relationships, divorced, separated or widowed. Approximately
73% of participants stated that they have no children. Moreover,
the majority (63.1%) of the study participants were in full-
time employment, 40.2% were educated to at least degree level,
and 51.1% had the lowest household income (≤ £39,999).
Finally, participants were asked to self-report their diagnosed
PCOS phenotype; 46.5% indicated that they had all three PCOS
diagnostic characteristics (i.e., hyperandrogenism, menstrual
disruption, and PCO), 13.5% PCO and menstrual disruption,
9.6% PCO and hyperandrogenism, 6.9% hyperandrogenism and
menstrual disruption, and the remaining 23.1% were unsure of
the PCOS phenotype with which they had been diagnosed.
When participants’ responses to the question about the impact
of COVID-19 restrictions on their sleep were dichotomized into
negative and no/positive responses, 242 participants reported
that they had experienced either a significant or small negative
effect upon their sleep, whilst the remaining 91 reported either
no such effect, or at least a small positive effect upon their
sleep. Using the ISI scoring guidelines, 44.2% of those reporting
negative effects met the scoring threshold (>14) for a diagnosis
of at least moderately severe clinical insomnia. Key outcomes
of interest were compared between these two study groups and
these findings are summarized in Table 2.
Overall, there were no differences between the study groups
regarding age, weight, body mass index (BMI), time since PCOS
diagnosis, or number of comorbidities. As expected, the self-
reported insomnia severity assessed by the ISI was significantly
higher in those who reported a negative effect of COVID-19
on their sleep quality compared to those who reported no such
effect or a relevant positive effect (Table 2). Furthermore, the
former also reported poorer QoL, as measured by the total
PCOSQOL score, whilst they also reported a greater impact
of PCOS and poorer mood in the corresponding PCOSQOL
domains. Finally, based on the corresponding DASS-21 scale
scores, those reporting a negative effect of COVID-19 on their
sleep quality also had statistically higher depression and stress
levels, but not anxiety, compared to those who reported no such
effect (Table 2).
For the entire study cohort, Spearman’s correlation tests
showed an inverse correlation between the ISI and PCOSQOL
total score (rs = −0.384, p < 0.001), and domain scores
for Impact of PCOS (rs = −0.379, p < 0.001), Infertility
(rs =−0.225, p < 0.001), Hirsutism (rs = −0.205, p < 0.001),
and Mood (rs = −0.405, p < 0.001). Furthermore, significant
positive correlations were also noted between the ISI and the
DASS-21 Depression (rs = 0.377, p< 0.001), Anxiety (rs = 0.410,
p < 0.001), and Stress (rs = 0.467, p < 0.001) scores. These
correlations between the ISI and the total PCOSQOL score, all
PCOSQOL domains apart from Hirsutism, and DASS-21 scores
TABLE 1 | Breakdown of socioeconomic and ethnicity characteristics of interest
for the study cohort of UK women with polycystic ovary syndrome [PCOS;




Mixed background 9 (2.7)
Asian or Asian British 8 (2.4)
Black or Black British 4 (1.2)
Other ethnic background 3 (0.9)





















Full-time employment 210 (63.1)
Part-time employment 47 (14.1)
Student 27 (8.1)




≤ £39,999 170 (51.1)
£40,000–£79,999 137 (41.1)
≥ £80,000 26 (7.8)
All percentage data has been rounded to one decimal place.
also remained statistically significant within each of the two
groups (data not shown).
Results of the OLR indicated that Stress, Anxiety, and
Depression, as measured by the DASS-21, alongside PCOSQOL
domain scores for Mood, Hirsutism, Infertility, and Impact of
PCOS were significant predictors of ISI score (all p-values < 0.01;
Table 3). Furthermore, we found that the DASS-21 variables
were the greatest predictors of ISI score, accounting for the
largest proportion of variance in the dependent variable [Stress:
Wald χ²: 87.23, OR: 1.23 (1.18, 1.29), R²N: 0.05, p < 0.0001;
Anxiety: Wald χ²: 64.06, OR: 1.19 (1.14, 1.25), R²N: 0.03,
p < 0.0001; Depression: Wald χ²: 55.5, OR: 1.15 (1.11, 1.20),
R²N: 0.03, p < 0.0001]. Finally, no participant characteristic
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significantly influenced the direction or magnitude of the OLR
(all p-values > 0.2).
DISCUSSION
To our knowledge, this is the first study to assess the self-
reported sleep quality of women with PCOS in the UK during
the lockdown/quarantine measures imposed in response to
TABLE 2 | Key outcomes of interest for the study cohort of UK women with
polycystic ovary syndrome (PCOS) when split into a dichotomous response
regarding the impact of the lockdown measures due to COVID-19 on sleep

















Age (years) 30.0 (9.0) 29.0 (9.0) 30.0 (10.3) 0.426
Years Since PCOS
Diagnosis
8.0 (9.9) 7.3 (9.8) 8.2 (12.0) 0.336
Weight (kg) 93.9 (37.9) 93.9 (37.2) 91.2 (37.5) 0.290
BMI (kg/m2 ) 34.8 (13.6) 35.0 (13.1) 34.0 (14.7) 0.322
PCOSQOL
Total Score 101.0 (60.5) 97.0 (59.0) 114.0 (65.8) 0.003
Impact of PCOS 40.0 (28.5) 38.0 (26.0) 50.5 (30.5) 0.001
Infertility 24.0 (27.0) 23.0 (27.0) 30.5 (26.5) 0.077
Hirsutism 16.0 (18.0) 16.0 (17.0) 17.5 (20.3) 0.348
Mood 17.0 (10.0) 16.0 (9.0) 21.0 (11.0) 0.001
DASS-21
Depression 18.0 (17.0) 18.0 (16.0) 13.0 (16.0) 0.014
Anxiety 10.0 (12.0) 12.0 (12.0) 10.0 (11.0) 0.094
Stress 18.0 (14.0) 18.0 (12.0) 15.0 (14.5) 0.007
Insomnia Severity 12.0 (9.5) 14.0 (8.0) 7.0 (8.0) <0.001
Comorbidities 1.0 (2.0) 1.0 (2.0) 1.0 (3.0) 0.737
Data are presented as median (interquartile range). Between group comparisons
performed by independent samples Mann-Whitney U-tests. Insomnia severity as
assessed by the validated Insomnia Severity Index (ISI). Significance was set at p < 0.05.
BMI, bodymass index; PCOSQOL, Polycystic ovary syndrome quality of life questionnaire;
DASS-21, Depression, Anxiety, and Stress Scale; P, asymptotic two-sided significance.
Values in a bold font correspond to P < 0.05.
the COVID-19 pandemic, and explore potential corresponding
associations with QoL and depression, anxiety, and stress levels
in this female population. Of note, according to the findings of
the present study ∼73% of the study participants reported that
their sleep quality had worsened since COVID-19 restrictions
were imposed. Interestingly, when compared to data from a
study in the general population during COVID-19 lockdown
measures (62), the prevalence of clinical insomnia based upon
the ISI among the women with PCOS of the present study
was markedly greater (∼35 vs. ∼10%). Our findings are in
accord with data reported from a web-based study in the Greek
general population during the national lockdown due to COVID-
19, where 37.6% of participants (particularly women) scored
above the threshold for insomnia based on a relevant validated
questionnaire (63). Prior to the COVID-19 pandemic, global
estimates for the prevalence of insomnia ranged between 3.9
and 22% (64), thus these findings suggest that there has been
an exacerbation of sleep disturbances (e.g., insomnia) during
this pandemic.
The present findings showing that the majority of women with
PCOS self-report negative effects upon their sleep during the
COVID-19 restrictions highlight insomnia and poor sleep health
as a significant problem in this female population. However, it
should be noted that it is difficult to determine the magnitude
of this problem/change without having relevant baseline
assessments before this pandemic. Indeed, due to practical
difficulties in studying women with PCOS in representative
population-based samples, there is an overall paucity of data
on the prevalence of sleep disturbances in this population to
allow precise comparisons (65). Notably, one common known
sleep disorder in women with PCOS is OSA, with a recent
meta-analysis reporting that OSA prevalence in women with
PCOS is 35% (95% confidence interval: 22.2–48.9%) which is
further increased in the presence of overweight/obesity (45).
Nevertheless, OSA does not appear to be a defining factor for
the findings of the present study, since only 1.2% of participants
indicated that they had received a medical diagnosis of OSA, and
there were no between group differences for BMI or additional
comorbidities (e.g., T2DM) that are often associated with PCOS
and OSA (26). Undiagnosed OSA is common in this female
population (26), and may also be present among the participants
TABLE 3 | Results from the ordinal logistic regression (OLR) for the study cohort of UK women with polycystic ovary syndrome (PCOS).
95% CI 95% CI
Predictor β Lower Upper SE Z OR Lower Upper Wald χ² R²N p
DASS-21 stress 0.21 0.17 0.25 0.02 9.055 1.23 1.18 1.29 87.23 0.05 < 0.0001
DASS-21 anxiety 0.17 0.13 0.22 0.02 7.793 1.19 1.14 1.25 64.06 0.03 < 0.0001
DASS-21 depression 0.14 0.11 0.18 0.01 7.314 1.15 1.11 1.20 55.5 0.03 < 0.0001
PCOSQOL mood −0.12 −0.1 −0.08 0.01 −7.692 0.88 0.86 0.91 62.49 0.02 < 0.0001
PCOSQOL hirsutism −0.03 −0.05 −0.01 0.008 −3.288 0.97 0.95 0.99 10.98 0.005 0.001
PCOSQOL infertility −0.03 −0.04 −0.01 0.006 −3.942 0.97 0.96 0.98 15.79 0.008 < 0.0001
PCOSQOL impact of PCOS −0.03 −0.04 −0.02 0.005 −6.771 0.96 0.95 0.97 48.01 0.02 < 0.0001
CI, Confidence Interval; β, beta-coefficient; SE, Standard Error; OR, Odds ratio; R²N , Nagelkerke’s pseudo-R²; PCOSQOL, Polycystic ovary syndrome quality of life questionnaire;
DASS-21, Depression, Anxiety, and Stress Scale (21 item). Values in a bold font correspond to P < 0.05.
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of this cohort, but whether this could be an underlying factor
contributing to the present findings requires further and more
targeted research.
Another mechanism contributing to sleep disturbances in this
study may relate to increased depression, anxiety, and stress
levels. Indeed, depression, anxiety and stress yield the largest
beta coefficients and account for the largest amount of variance
to ISI scores in the results of the ordinal logistic regression in
the present study. Of interest, when the whole study cohort was
considered, 51.5% reported that they had previously received
a medical diagnosis of anxiety and/or stress. Whilst it was
unclear whether these diagnoses were made prior to, or during
the COVID-19 pandemic, additional insight can be gained
from the self-reported DASS-21 scores. Based on this validated
questionnaire, the prevalence rates of at least mild depression,
anxiety, and stress in the study cohort were 80.5, 70.6, and 64.6%,
respectively, which are higher than the reported corresponding
medical diagnoses. Notably, these are also higher than those
reported by a meta-analysis for depression (33.7%; 95% CI: 27.5–
40.6), anxiety (31.9%; 95% CI: 27.5–36.7), and stress (29.6%; 95%
CI: 24.3–35.4) in the general population during the COVID-
19 pandemic (66). Collectively, these data suggest that during
the current pandemic, women with PCOS are experiencing
a greater psychological burden than the general population,
with a markedly higher prevalence. This is in accord with the
latest international evidence-based guidance on PCOS, which
highlights that, irrespective of a global pandemic, women with
PCOS are more likely to experience depression and anxiety (67).
Other reported risk factors for decreased sleep quality during
the COVID-19 pandemic are changes to sleep patterns (62),
worries about health (68), financial consequences (69), social
interactions (70), reduced physical activity (63), and gender with
women being reportedly 56%more likely than men to experience
sleep disruption during this pandemic (71). As such, it is plausible
that such factors further contribute to a potential multifactorial
effect upon an already “at risk” population (72), which clearly
exacerbates sleep disruption and may result in reduced QoL.
Indeed, the results of the present study support this notion,
since women with PCOS who reported negative sleep effects
during the COVID-19 pandemic also exhibited reduced QoL (as
measured by the PCOSQOL) compared to those without any,
or with positive effects on sleep. Based on the corresponding
PCOSQOL domains, this associationwas apparently burdened by
the impact of PCOS and affected mood in the study participants.
However, what cannot be determined by the present findings is
the directional role of sleep disruption in the aforementioned
milieu for which further studies are clearly needed.
Interestingly, longitudinal studies have previously reported
associations between sleep disorders, anxiety, and depression
(73, 74), which are known to independently impair QoL (75).
Moreover, it has been purported that there is a bidirectional
relationship between sleep quality and mental well-being (76),
with sleep quality independently predicting the prevalence of
anxiety and/or depression, whilst anxiety and depression are also
predictors for reduced sleep quality (42, 77). Due to the nature of
our analysis, the current study is unable to determine the causal
direction between sleep and mental well-being. However, it is
likely that the COVID-19 pandemic has created an overarching
environment which further exacerbates this relationship with
the net result being further impairments of mental health and
sleep quality leading to reduced QoL. As prior to the COVID-
19 pandemic, women with PCOS were already recognized as
a patient population at an increased risk of anxiety/stress,
depression, sleep disorders, and impaired QoL (18, 19); the
disrupting circumstances of this pandemic mean then that there
should be a renewed and heightened focus from healthcare
professionals to ensure that adequate support and treatment
provision is available to reduce and, where possible, prevent
further comorbidity and impaired QoL in these women (16).
Study Limitations
There are certain limitations which should be acknowledged
in the present study. This study relied upon participant self-
report which can lead to a degree of decreased clarity/accuracy
in the provided answers, thus inevitably introducing a degree
of information bias to the study findings. For example, it is
known that individuals tend to over-report their height and
under-report their weight (78), an effect which appears to be
further exaggerated in individuals with overweight/obesity (79).
This may lead to discrepancies in self-reported anthropometric
data which, given the key role of metabolic health in PCOS
severity/comorbidity (80) and sleep quality (26) may impact to
some degree on the study findings. However, this methodology
is frequently employed in studies of this nature, whilst validated
instruments/questionnaires were utilized to capture key study
data of interest. Another study limitation is the lack of
comparative baseline data for the study cohort for a period prior
to the COVID-19 pandemic. The study survey questions asked
about changes in sleep quality due to COVID-19 restriction
measures, but without validated baseline measurements, it is not
possible to quantify the exact extent to which the corresponding
outcomes have been affected. This issue could be addressed to
some degree at a follow-up time point when current restrictions
have been eased/lifted. To this aim, the relevant prospective
follow-up of this study cohort has been planned. Furthermore,
although the large sample size in the present study is a distinct
strength, it is accompanied by some inherent limitations. For
instance, OLR yielded significant R²N for all variables, yet most
were of little practical significance; thus, in interpreting these
results, the potential fallacy of large sample sizes must be
considered (81). Finally, as this is a cross-sectional study, the
present findings cannot be used to infer conclusions regarding
the temporal/causal relationship between the noted negative
impact on sleep and reported levels of depression/stress.
CONCLUSION
The present study offers a novel insight regarding the self-
reported sleep quality of women with PCOS during the COVID-
19 pandemic lockdown, and how this is associated with QoL and
depression, anxiety, and stress levels in this population. Based
on our present findings, it is evident that the majority of UK
women with PCOS in this study cohort feel that the applied
measures imposed in response to the COVID-19 pandemic had a
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negative impact on the quality of their sleep, with high prevalence
of insomnia. There is also evidence that those women with
PCOS and impaired sleep have greater levels of psychological
morbidity (e.g., depression/stress) and reduced QoL. Whilst it
appears that the restrictive measures due to COVID-19 have
increased this comorbidity burden in these women with PCOS,
the exact magnitude of the impact of this global pandemic
upon these parameters and the underlying temporal/causal
relationship is less clear. Nevertheless, it has previously been
reported that during such disease outbreaks, the number of
individuals whose mental health is negatively affected can be
greater than the number affected by the infection (82), and
that the mental health implications and their prevalence can be
even more significant than the epidemic itself (83). Another key
message to consider based on the present study is that there
are certain groups that may remain relatively overlooked despite
being particularly vulnerable during this pandemic. Women
with PCOS should be considered within these parameters, since
they are at increased risk of cardio-metabolic complications
which, in turn, may increase the risk of severe COVID-19,
whilst they are also susceptible to significant psychological
comorbidity which, regardless of COVID-19, may impair their
overall well-being.
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